The Medicines Company (MDCO)
(Delayed Data from NSDQ)
$31.89 USD
+0.61 (1.95%)
Updated May 3, 2019 04:00 PM ET
After-Market: $31.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.89 USD
+0.61 (1.95%)
Updated May 3, 2019 04:00 PM ET
After-Market: $31.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FNY
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
by Ekta Bagri
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Alnylam's Kidney Disease Drug Succeeds in Late Stage Study
by Zacks Equity Research
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Alnylam Gets Second Product Approval Amid Stiff Competition
by Zacks Equity Research
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal
by Kinjel Shah
Here are four stocks that boast promising prospects and are most likely to be takeout targets.
A Day of Mergers: TIF, AMTD, MDCO & More
by Zacks Equity Research
A Day of Mergers: TIF, AMTD, MDCO & More
Biggest Merger Monday in Awhile: TIF, AMTD, MDCO & More
by Mark Vickery
While Tiffany's agrees to terms with French luxury brand LVMH, Schwab buys Ameritrade, Novartis takes Medicines Co. and more.
Novartis (NVS) to Acquire The Medicines Company for $9.7B
by Zacks Equity Research
Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
The Medicines Company to be Acquired by Novartis for $9.7B
by Zacks Equity Research
The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria
by Zacks Equity Research
Alnylam (ALNY) gets FDA approval for givosiran injection, to be marketed by the trade name of Givlaari, for the treatment of adults with AHP.
Implied Volatility Surging for Medicines Company (MDCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
Medicines Company Up on Rumors of Potential Buyout by Novartis
by Zacks Equity Research
The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.
Healthcare ETF (RYH) Hits New 52-Week High
by Sanghamitra Saha
This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?
Medicines Company Posts Full Inclisiran Data From ASCVD Study
by Zacks Equity Research
The Medicines Company (MDCO) reports detailed data from the phase III ORION-10 study on its lead candidate inclisiran to treat patients with ASCVD.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.
Medicines Co. (MDCO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Medicines Co. (MDCO) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Medicines Company's Inclisiran Succeeds in Pivotal Studies
by Zacks Equity Research
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.
Medicines Company (MDCO) Jumps: Stock Rises 5.5%
by Zacks Equity Research
Medicines Company (MDCO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.